AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
38.35
-0.80 (-2.04%)
At close: 4:03PM EST

38.44 +0.08 (0.21%)
Pre-Market: 5:47AM EST

Stock chart is not supported by your current browser
Previous Close39.15
Open39.20
Bid38.46 x 1000
Ask38.50 x 800
Day's Range38.17 - 39.28
52 Week Range32.69 - 41.78
Volume4,360,587
Avg. Volume4,570,047
Market Cap97.008B
Beta (3Y Monthly)0.66
PE Ratio (TTM)40.16
EPS (TTM)0.95
Earnings DateN/A
Forward Dividend & Yield1.40 (3.58%)
Ex-Dividend Date2018-08-09
1y Target Est43.04
Trade prices are not sourced from all markets
  • Zacks15 hours ago

    Merck to Acquire Europe's Antelliq Group for $2.4 Billion

    Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.

  • How Is AstraZeneca Faring in Chinese Markets?
    Market Realist19 hours ago

    How Is AstraZeneca Faring in Chinese Markets?

    How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca (AZN) reported revenues worth $2.85 billion from China, which is a YoY rise of 33% on an actual basis and 27% on a CER (constant exchange rate) basis. China accounted for around 56% of the company’s total emerging markets sales and 19% of the total revenues earned by the company in the first nine months of 2018.

  • These New Products Are Driving AstraZeneca’s Growth in Fiscal 2018
    Market Realist22 hours ago

    These New Products Are Driving AstraZeneca’s Growth in Fiscal 2018

    How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca reported oncology revenues of $4.26 billion, which is a YoY increase of 47% on an actual basis and 44% on a constant exchange rate (or CER) basis. In the first nine months of 2018, AstraZeneca reported new cardiovascular, renal, and metabolism (or CVRM) product sales worth $2.90 billion, which is a YoY rise of 14% on an actual basis and 12% on a CER basis.

  • PR Newswire23 hours ago

    Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases

    - Pyramid Biosciences to exclusively develop AstraZeneca's novel cell surface receptor (TRK) program - Targeting range of dermatological and inflammatory diseases, including psoriasis and atopic dermatitis ...

  • What Are AstraZeneca’s Growth Drivers in Fiscal 2018?
    Market Realist4 days ago

    What Are AstraZeneca’s Growth Drivers in Fiscal 2018?

    How Is AstraZeneca Positioned in December? In the third quarter, AstraZeneca (AZN) managed to surpass consensus adjusted EPS estimates by $0.27. In the third quarter, AstraZeneca reported operating profit of $851 million, which is a YoY decline of 26% on an actual basis and 21% on a constant exchange rate (or CER) basis.

  • Zacks4 days ago

    Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus

    AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.

  • A Look at AstraZeneca’s Expense Projections for Fiscal 2018
    Market Realist4 days ago

    A Look at AstraZeneca’s Expense Projections for Fiscal 2018

    How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca (AZN) reported selling, general, and administrative (or SG&A) expenses of $7.43 billion, which is a YoY rise of 4% on an actual basis and 1% on a constant exchange rate (or CER) basis. The company reported core SG&A expenses of $6.21 billion in the first nine months of 2018, which is a YoY rise of 10% on an actual basis and 7% on a CER basis.

  • What Are AstraZeneca’s Margin Projections for Fiscal 2018
    Market Realist4 days ago

    What Are AstraZeneca’s Margin Projections for Fiscal 2018

    How Is AstraZeneca Positioned in December? AstraZeneca (AZN) reported a gross margin of 79.8% in the first nine months of 2018, which is a decline of 200 basis points on a YoY basis. Wall Street analysts expect AstraZeneca to report a gross margin of 80.40% in fiscal 2018, which would be a YoY decline of 39 basis points.

  • What to Expect from AstraZeneca’s Earnings in Fiscal 2018
    Market Realist5 days ago

    What to Expect from AstraZeneca’s Earnings in Fiscal 2018

    How Is AstraZeneca Positioned in December? In its third-quarter earnings conference call, AstraZeneca (AZN) reiterated its core EPS guidance of $3.30–$3.50 at a constant exchange rate (or CER). In the third quarter, AstraZeneca posted core EPS of $0.71, which is a YoY decline of 37% on an actual basis and 33% on a CER basis.

  • What Analysts Recommend for AstraZeneca in December
    Market Realist5 days ago

    What Analysts Recommend for AstraZeneca in December

    How Is AstraZeneca Positioned in December? On December 11, AstraZeneca (AZN) closed at $38.66, which is 0.65% higher than its previous closing price. AstraZeneca has risen 3.40% from $38.51 on November 1 to $39.82 on November 30.

  • GlobeNewswire5 days ago

    Guardant Health Partners with AstraZeneca to Develop Blood-Based Companion Diagnostic Tests for Tagrisso and Imfinzi

    FDA grants breakthrough device designation to GuardantOMNI test usedfor plasma-based tumor mutational burden analysis in AstraZeneca trial Agreement covers immunotherapy and.

  • What’s the Market Opportunity for Zejula?
    Market Realist5 days ago

    What’s the Market Opportunity for Zejula?

    How Is Tesaro Positioned in December? As per GlaxoSmithKline’s (GSK) analyst call transcript, Tesaro’s (TSRO) Zejula is competing with AstraZeneca’s (AZN) Lynparza and Clovis Oncology’s (CLVS) Rubraca as maintenance therapy in the second-line platinum-sensitive ovarian cancer indication. GlaxoSmithKline (GSK) has estimated the annual incidence of these patients in the US market to be around 5,000.

  • Thomson Reuters StreetEvents5 days ago

    Edited Transcript of AZN.L earnings conference call or presentation 26-Jul-18 11:30am GMT

    Q2 2018 AstraZeneca PLC Earnings Call

  • A Look at Expansion Plans for Zejula
    Market Realist6 days ago

    A Look at Expansion Plans for Zejula

    On October 22, 2018, AstraZeneca (AZN) issued a press release announcing positive results from Phase 3 trial SOLO-1, which evaluated PARP inhibitor Lynparza as a first-line maintenance therapy in ovarian cancer patients with germline BRCA (or gBRCA) mutations. The robust data from this trial in terms of improvement in progression-free survival has made a strong case for the advancement of other PARP inhibitors in the maintenance setting for first-line ovarian cancer patients.

  • Here is What Hedge Funds Think About AstraZeneca plc (AZN)
    Insider Monkey6 days ago

    Here is What Hedge Funds Think About AstraZeneca plc (AZN)

    The market has been volatile as the Federal Reserve continues its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points through November 16th. SEC filings and hedge fund […]

  • InvestorPlace7 days ago

    Moderna Stock Ushers In the Next Wave of Biotech

    Moderna (NASDAQ:MRNA) went public on Dec. 7, raising $604 million on a market cap of $7.5 billion. The IPO met the goal, but a bad day on Wall Street sent the shares plummeting. It’s because Moderna represents the next wave in drug discovery. Like Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna is less a bet on particular drugs than on a method for finding them.

  • Benzinga7 days ago

    Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

    Clovis Oncology Inc (NASDAQ: CLVS ) has emerged as a strong takeover candidate following GlaxoSmithKline plc (NYSE: GSK )'s proposed acquisition of TESARO Inc (NASDAQ: TSRO ), according to Gabelli Research. ...

  • Can Moderna Stock Recover From Its Initial Setback?
    Motley Fool7 days ago

    Can Moderna Stock Recover From Its Initial Setback?

    The largest biotech unicorn of its time is trying to get back up after stumbling out of the gate.

  • Is Bristol Myers Squibb Co. (BMY) A Good Stock To Buy According To Hedge Funds?
    Insider Monkey9 days ago

    Is Bristol Myers Squibb Co. (BMY) A Good Stock To Buy According To Hedge Funds?

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • New Biotech IPO Dropped a Unicorn-Sized Value on Its First Day
    Bloomberg11 days ago

    New Biotech IPO Dropped a Unicorn-Sized Value on Its First Day

    The $1.4 billion Moderna lost in value is greater than the market value of more than half the companies in the Nasdaq Biotechnology Index. The company boasts partnerships with sector juggernauts including Merck & Co. and AstraZeneca Plc, so its growth prospects have attracted notable attention across the sector.

  • Reuters11 days ago

    AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study

    The results come after AstraZeneca warned last month that its immunotherapy treatment Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares. AstraZeneca has been seen as having a head start in the race for cancer treatments, and Imfinzi was aiming to be the new standard of care in treating early inoperable stage III lung cancer.

  • Here's Why Agenus Stock Popped 51.6% in November
    Motley Fool12 days ago

    Here's Why Agenus Stock Popped 51.6% in November

    One big drugmaker's pain was this biotech's gain last month.